Open Access
Instituto superior de ci ncias da sa⁄de
Egas Moniz
- 01 Jan 2014
TL;DR: The regulation of feeding behavior also involves the monoamines dopamine, noradrenalin and serotonin involved in the reward center, a system that values the intake by the feeling of pleasure, and the endocannabinoid system that protects from anxiety and stimulates feeding.
read more
Abstract: 5 Abstract Feeding behavior depends on the balance between food intake and energy expenditure. This regulation occurs in the brain where the hypothalamus plays a key role. The hypothalamus receives adiposity signals by insulin and leptin that gives information about the state of energy reserves. When their levels are low, hypothalamus nuclei send signals through the orexigenic neuropeptides NPY, AgRP, CRH and orexins and ghrelin, a peripheral peptide that stimulate food intake. During ingestion, the first signals received by the brain are the pleasure channeled through the reward system, and the distension of the stomach that is communicated to the brainstem via the vagus nerve. Digestion causes the release of hormones that act as peripheral satiety signals, operating in the brainstem or in the arcuate nucleus (ARC) of the hypothalamus. Examples of such hormones are amylin, pancreatic polypeptide (PP), oxyntomodulin (OXM), cholecystokinin (CCK), glucagon-related peptide (GLP1) and peptide YY (PYY). The regulation of feeding behavior also involves the monoamines dopamine, noradrenalin and serotonin involved in the reward center, a system that values the intake by the feeling of pleasure, and the endocannabinoid system that protects from anxiety and stimulates feeding. Actually, there are few alternative drugs to treat obesity that are effective and safe because the pathways involved in feeding behavior are often easily compensated by other pathways, and are involved in the regulation of other systems.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
•Journal Article
BRIEF COMMUNICATION ARISING: Gut hormone PYY3-36 physiologically inhibits food intake
Rachel L. Batterham,Michael A. Cowley,Caroline J. Small,Herbert Herzog,Mark A Cohen,C. L. Dakin,Alison M. Wren,Audrey E. Brynes,Malcolm J. Low +8 more
TL;DR: The authors showed that post-prandial elevation of PYY3-36 may act through the arcuate nucleus Y2R to inhibit feeding in a gut-hypothalamic pathway.
1.9K
•Journal Article
MDS Clinical Diagnostic Criteria for Parkinson's Disease (S19.001)
Ronald B. Postuma,Daniela Berg +1 more
TL;DR: The International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson9s disease as discussed by the authors have been proposed for clinical diagnosis, which are intended for use in clinical research, but may also be used to guide clinical diagnosis.
1.6K
•Journal Article
Association of cocaine- and amphetamine-regulated transcript-immunoreactive elements with thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and its role in the regulation of the hypothalamic-pituitary-thyroid axis during fasting
Csaba Fekete,Emese Mihály,Lu Guang Luo,Joseph Kelly,Jes Thorn Clausen,Quan Fu Mao,William M. Rand,Larry G. Moss,Michael J. Kuhar,Charles H. Emerson,Ivor M. D. Jackson,Ronald M. Lechan +11 more
TL;DR: In this paper, triple-labeling fluorescent in situ hybridization and immunofluorescence were performed to reveal the morphological relationships between pro-TRH mRNA-containing neurons and CART- and alpha-MSH-immunoreactive (IR) axons.
151
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
Erik Näslund,Neil A. King,S. Mansten,N. Adner,Jens J. Holst,M. K. Gutniak,Per M. Hellström +6 more
- 01 Jan 2004
TL;DR: In this article, a 5-day infusion of recombinant glucagon-like peptide-1 (7-36)amide (rGLP-1) was shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion.
149
References
Ophthalmic Drug Dosage Forms: Characterisation and Research Methods
TL;DR: In this article, the authors describe hitherto developed drug forms for topical ocular administration, that is, eye drops, ointments, in situ gels, inserts, multicompartment drug delivery systems, and ophthalmic drug forms with bioadhesive properties.
Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach
Dorothea Emig,Alexander E. Ivliev,Olga Pustovalova,Lee Lancashire,Svetlana Bureeva,Yuri Nikolsky,Marina Bessarabova +6 more
TL;DR: A network-based approach for the prediction of drug targets for a given disease and the ability of the method to identify non-suspected repositioning candidates using diabetes type 1 as an example is demonstrated.
Review: ex vivo engineering of living tissues with adult stem cells.
TL;DR: Progress and challenges in ex vivo tissue engineering with adult stem cells are examined and future advances in stem cell biology and scaffold design will ultimately improve the efficacy of tissue substitutes as implants, in research, and as extracorporeal devices.
255
Rapid development of tolerance to the behavioural actions of cholecystokinin
TL;DR: No change was detected in either body weight or total daily food consumption at any time point during 2 weeks of intraperitoneally infused CCK, providing the first evidence that rapid and reversible tolerance develops to the actions of a gut peptide.
255
Primary pulmonary hypertension and fenfluramine use.
TL;DR: The results do not accord with earlier reports that PPH associated with fenfluramine is less severe and has a better outcome, and the results of a European case-control study should give new insights into risk factors for PPH and the cause and effect relation with fENFLuramine.
253